Clinical Trials Logo

Clinical Trial Summary

Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring hormone in the body. It is believed that reducing the level of cortisol will be a benefit in the treatment of Alzheimer's disease.

The XanaHES study is testing the safety and tolerability of Xanamem. It is planned to enrol approximately 84 participants, male and female aged from 50 to 75 who are in good health, in the study at 1 centre in Australia.

The XanaHES Phase I study is a single-blind study. Subjects will be randomised to receive either 20mg once daily Xanamem or Placebo in cohort 1. Once all subjects have completed the study treatment of 12 weeks, a dose escalation committee will decide if a new cohort, cohort 2, with 30mg once daily vs placebo is started.


Clinical Trial Description

This is a Phase I, randomised, single-centre, single-blind, placebo-controlled study to assess the safety, tolerability of oral Xanamem once daily in healthy elderly subjects.

It is planned to randomise approximately 84 subjects, 42 in each cohort, at a single site in Australia.

Cohort 1 starts with a 20mg QD dose vs matching placebo. A Dose Escalation Committee will review the results from cohort 1 and provide a recommendation to proceed with Cohort 2 randomisation which involves a dose escalation to 30mg.

At the Baseline visit (Week 0), eligible subjects will be randomised on a 30:12 ratio to receive either Xanamem administered orally QD (treatment group) or matching placebo (placebo group). Subjects will return to the study site for visits at Week 2, Week 4, Week 6, Week 8, Week 10, End of Treatment (Week 12) and Follow-up (4 weeks post last dose of study drug) visits, at which study assessments will be performed.

Ad hoc telephone contact may also occur at any other time-point throughout the study, if deemed necessary by the investigator/study nurse, or if the subject wishes to report an adverse event (AE).

Subjects will be interviewed and examined at the study site at each visit and will complete a variety of questionnaires, routine safety evaluations and nerve function tests.

A central reader will review every Nerve Function Monitoring (NFM) assessment performed for each subject for Potential Nerve Safety Signals (PNSS).

Optional cerebrospinal fluid (CSF) sampling will be performed at baseline and end of treatment visits for a small subgroup of subjects, who provide additional consent. Subjects who do not provide consent for this optional sub-study will still be eligible for the main study.

The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of up to 4 weeks, a single-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 1.5 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03830762
Study type Interventional
Source Actinogen Medical
Contact
Status Completed
Phase Phase 1
Start date January 21, 2019
Completion date January 7, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05152368 - Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy Phase 1
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Completed NCT02549534 - Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer N/A
Active, not recruiting NCT02701075 - MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain N/A
Completed NCT01196442 - Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer N/A
Completed NCT00763087 - Effect of Weight-Bearing Exercise on People With Diabetes and Neuropathic Feet N/A
Completed NCT00079807 - Painful HIV Neuropathy and Alpha-Lipoic Acid Phase 1/Phase 2
Completed NCT03292328 - Yoga for Symptoms of Nerve Damage Caused by Chemotherapy N/A
Active, not recruiting NCT05379140 - Use Therapeutic Chinese Massage to Treat Peripheral Neuropathy in People With HIV N/A
Recruiting NCT05673746 - Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer N/A
Completed NCT05189535 - "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients" Phase 2/Phase 3
Recruiting NCT06219590 - Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy N/A
Enrolling by invitation NCT05595109 - Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients Phase 2/Phase 3
Completed NCT05916118 - Exercise and Oxaliplatin-induced Peripheral Neuropathy N/A
Withdrawn NCT03881748 - Clinical Trial of Acupuncture for Chemotherapy-Induced Peripheral Neuropathy N/A
Not yet recruiting NCT03112057 - Visualize Nociceptor Changes in Neuropathic Human N/A
Completed NCT02936843 - Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Phase 2/Phase 3
Terminated NCT01458015 - Tapentadol Versus Oxycodon - a Mechanism-based Treatment Approach in Neuropathic Pain Phase 4
Completed NCT01006408 - Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy N/A
Completed NCT00471445 - Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Phase 3